Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism

Nephrology Dialysis Transplantation

Volumn 27, Issue 2, 2012, Pages 784-790

  Koizumi, Masahiro ^a,b   Komaba, Hirotaka ^a,b   Nakanishi, Shohei ^b   Fujimori, Akira ^c,d   Fukagawa, Masafumi ^a,b  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Chibune Kidney and Dialysis Clinic   (Japan)

^d Konan Hospital   (Japan)

Author keywords

cinacalcet hydrochloride; FGF23; haemodialysis; parathyroid hormone; secondary hyperparathyroidism

Indexed keywords

22 OXACALCITRIOL; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; CINACALCET; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHORUS; REGPARA; SEVELAMER; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; FIBROBLAST GROWTH FACTOR 23 BLOOD LEVEL; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SECONDARY HYPERPARATHYROIDISM; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBROBLAST GROWTH FACTORS; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NAPHTHALENES; PARATHYROID HORMONE; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 81255194004     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr384     Document Type: Article

References (43)

1. Drüeke TB. Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 2000; 11: 1141-1152
2. Fukagawa M, Komaba H, Onishi Y et al. Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan: baseline data from the MBD-5D. Am J Nephrol 2011; 33: 427-437
3. Komaba H, Fukagawa M. FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int 2010; 77: 292-298
4. Gutierrez OM. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis. Clin J Am Soc Nephrol 2010; 5: 1710-1716
5. Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 2008; 118: 3820-3828
6. Saito H, Kusano K, KinosakiMet al. Human fibroblast growth factor-23 mutants suppress Na-dependent phosphate cotransport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem 2003; 278: 2206-2211
7. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429-435
8. Shigematsu T, Kazama JJ, Yamashita T et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004; 44: 250-256
9. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215
10. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003-4008
11. Komaba H, Goto S, Fujii H et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 2010; 77: 232-238
12. Galitzer H, Ben-Dov IZ, Silver J et al. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010; 77: 211-218
13. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: theMild toModerate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608
14. Jean G, Bresson E, Terrat JC et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 2009; 24: 948-955
15. Gutiérrez OM, Januzzi JL, Isakova T et al. Fibroblast growth factor-23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552
16. Gutiérrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592
17. Kazama JJ, Sato F, Omori K et al. Pretreatment serum FGF23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 2005; 67: 1120-1125
18. Nakanishi S, Kazama JJ, Nii-Kono T et al. Serum fibroblast factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005; 67: 1171-1178
19. Nishi H, Nii-Kono T, Nakanishi S et al. Intravenous calcitriol therapy increases serum concentration of fibroblast growth factor 23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 2005; 101: c94-c99
20. Koiwa F, Kazama JJ, Tokumoto A et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005; 9: 336-339
21. Oliveira RB, Cancela AL, Graciolli FG et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010; 5: 286-291
22. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525
23. Fukagawa M, Yumita S, Akizawa T et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 2008; 23: 328-335
24. Fishbane S, ShapiroWB, Corry DB et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 2008; 3: 1718-1725
25. Komaba H, Nakanishi S, Fujimori A et al. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010; 5: 2305-2314
26. Guideline Working Group, Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 2008; 12: 514-525
27. Payne RB, Little AJ, Williams RB et al. Interpretation of serum calcium levels in patients with abnormal serum proteins. Br Med J 1973; 4: 643-646
28. Wetmore JB, Liu S, Krebill R et al. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 2010; 5: 110-116
29. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counterregulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006; 17: 1305-1315
30. Marie PJ. The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis. Bone 2010; 46: 571-576
31. Kobayashi K, Imanishi Y, Miyauchi A et al. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol 2006; 154: 93-99
32. Shimada T, Yamazaki Y, Takahashi M et al. Vitamin D receptorindependent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 2005; 289: F1088-F1095
33. Silver J, Naveh-Many T. Phosphate and the parathyroid. Kidney Int 2009; 75: 898-905
34. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005; 90: 1519-1524
35. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006; 91: 3144-3149
36. Finch JL, Tokumoto M, Nakamura H et al. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol 2010; 298: F1315-F1322
37. Lavi-Moshayoff V, Wasserman G, Meir T et al. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010; 299: F882-F889
38. Sato T, Tominaga Y, Ueki T et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 2004; 44: 481-487
39. Cunningham J, Danese M, Olson K et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793-1800
40. Block GA, Zaun D, Smits G et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 2010; 78: 578-589
41. Fukagawa M, Kitaoka M, Yi H et al. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patient. Nephron 1994; 68: 221-228
42. Okuno S, Ishimura E, Kitatani K et al. Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2003; 18: 2613-2621
43. Tominaga Y, Inaguma D, Matsuoka S et al. Is the volume of the parathyroid gland a predictor of maxacalcitol response in advanced secondary hyperparathyroidism? Ther Apher Dial 2006; 10: 198-204